S-1: Oragenics Launches $20M Equity Offering to Fund Concussion Drug Development Amidst Going Concern Doubts and NYSE Listing Challenges

Oragenics, Inc. is seeking to raise up to $20 million through an offering of Series H Preferred Stock and Warrants to fund its ONP-002 concussion clinical trials and address significant financial challenges, including an auditor's going concern doubt and NYSE American listing non-compliance.

Summary

• Oragenics, Inc. is offering up to 800,000 shares of Series H Convertible Preferred Stock and warrants to purchase an equal number of Series H Preferred Stock, with a combined public offering price of $25.00 per unit.
• The company anticipates net proceeds of approximately $18.25 million from the offering, assuming the maximum amount is sold and no warrants are exercised, which will be used to fund ONP-002 concussion clinical trials, repay a $3 million Bridge Note, and for general working capital.
• Oragenics is a development-stage biopharmaceutical company primarily focused on ONP-002, a neurosteroid for mild traumatic brain injury (mTBI or concussion), delivered intranasally.
• ONP-002 has successfully completed preclinical animal studies and a Phase 1 clinical trial, demonstrating safety and tolerability in healthy human subjects.
• The company plans to initiate a Phase 2a feasibility study for ONP-002 in New Zealand in Q2/Q3 2025, followed by a Phase 2b proof of concept study in the US.
• Oragenics faces significant financial distress, having incurred substantial losses since its inception, and its auditor has expressed 'substantial doubt about its ability to continue as a going concern'.
• The company is currently non-compliant with NYSE American continued listing standards related to stockholders' equity and sustained net losses, with a deadline of October 18, 2025, to regain compliance.
• The offering is on a 'best efforts' basis with no minimum purchase requirements, creating uncertainty regarding the actual amount of capital that will be raised.
• Anti-dilution provisions in the Series H Preferred Stock could lead to significant future dilution for common shareholders if the company issues securities at a lower price in subsequent offerings, with no floor price on the Conversion Price.

Sentiment

Score: 3

Explanation: The sentiment is low due to severe financial distress, including an auditor's going concern doubt, significant accumulated losses, and ongoing NYSE listing non-compliance. While there are positive developments in clinical trials and intellectual property for ONP-002, the fundamental financial instability and the 'best efforts' nature of the offering introduce substantial risk and uncertainty for investors.

Positives

• ONP-002 has completed Phase 1 clinical trials, demonstrating safety and tolerability in healthy human subjects.
• Preclinical studies for ONP-002 showed rapid and broad biodistribution in the brain, reducing swelling, inflammation, and oxidative stress, with an excellent safety profile.
• Animal studies suggest ONP-002 has an equivalent, and potentially superior, neuroprotective effect compared to related neurosteroids, with positive behavioral outcomes.
• A new proprietary formulation for ONP-002 has been developed, believed to significantly increase bioavailability and improve intranasal drug delivery and adhesion.
• ONP-002 successfully completed cardiotoxicity and genotoxicity studies, addressing key FDA requirements prior to clinical trials.
• The company secured Human Research Ethics Committee (HREC) approval in Australia to initiate a Phase II clinical trial for ONP-002.
• A strategic partnership with BRAINBox Solutions aims to create a comprehensive 'trigger-to-treat' platform for traumatic brain injury.
• The company benefits from a currency exchange advantage and a tax rebate from the Australian government for Research and Development performed in Australia.
• Oragenics has experienced medical advisors, including Dr. James Kelly (Chief Medical Officer) and Dr. William Frank Peacock (Chief Clinical Officer), specializing in neurology and emergency medicine.

Negatives

• The company has incurred significant losses since its inception and possesses limited financial resources, with no current revenues.
• The auditor has expressed 'substantial doubt about our ability to continue as a going concern', indicating significant financial risk.
• Current cash and the anticipated net proceeds from this offering are insufficient to fund the ONP-002 product candidate through regulatory approval, necessitating further capital raises.
• Oragenics is not in compliance with NYSE American continued listing standards (Sections 1003(a)(i), (ii), and (iii) related to stockholders' equity and net losses) and faces potential delisting if compliance is not achieved by October 18, 2025.
• The offering is on a 'best efforts' basis with no minimum amount required, meaning the company may not raise sufficient funds to meet its objectives or repay the Bridge Note.
• The Offering Price and Warrant exercise price were determined on an 'arbitrary basis' and may not reflect the actual market value of the securities.
• Anti-dilution provisions in the Series H Preferred Stock could lead to substantial future dilution for common shareholders if the company issues securities at a lower price, as there is no floor price on the Conversion Price.
• There is a risk of not having sufficient authorized shares to satisfy Preferred Stock conversions if the Conversion Price is significantly reduced, which would require time-consuming and expensive shareholder approval.
• There is no established public trading market for the Series H Preferred Stock or the Warrants, limiting their liquidity.
• The company has an outstanding Bridge Note of $3,000,000 (issued with a 20% original issue discount) that matures on July 14, 2025, and must be repaid from the offering proceeds to avoid default.
• Oragenics has limited neurology-specific experience in key areas such as manufacturing, regulatory affairs, and commercialization.
• None of the company's product candidates have received regulatory approval for sale.

Risks

• The company has incurred significant losses since its inception, has limited financial resources, does not generate any revenues, and will need to raise additional capital in the future.
• The company may not be able to secure additional funding, and its auditor has expressed substantial doubt about its ability to continue as a going concern.
• The company may not be able to satisfy the continued listing standards of the NYSE American and may be delisted.
• The amount raised in this offering may not be sufficient to pursue business goals or repay the outstanding Bridge Note, potentially leading to default.
• The offering price and warrant exercise price were determined arbitrarily and may not be indicative of market value, and there is no established public trading market for the Preferred Stock or Warrants.
• Purchasers of Preferred Stock will experience immediate and substantial dilution upon conversion into Common Stock, and further dilution may occur due to anti-dilution provisions in the Preferred Stock (no floor price on Conversion Price) and future equity offerings.
• The company may not receive approval to commence its clinical trials in New Zealand or other jurisdictions.
• The company has limited neurology-specific research, development, manufacturing, testing, regulatory, commercialization, sales, distribution, and marketing experience.
• None of the company's product candidates have been approved for sale, and if they are not successfully developed, the company may not be able to continue as a going concern.
• Approved product candidates will face significant competition from companies with greater resources and experience, and ONP-002 may face competition from biosimilars.
• The market opportunities for neurology product candidates may be smaller than anticipated, and market acceptance is uncertain.
• Reliance on third-party manufacturers and suppliers poses a risk if they fail to meet requirements.
• Loss of key personnel or inability to hire successors could harm the business.
• Product candidates may be ineffective or harmful in humans.
• The company may not be successful at acquiring, investing in, or integrating businesses, or entering into joint ventures or divesting businesses.
• The company's research and development efforts are largely dependent on intellectual property and biological materials licenses, and there is a risk of inability to protect intellectual property or face infringement claims.
• Security breaches and other disruptions to information technology systems could compromise information and expose the company to liability.
• Product candidates are subject to substantial government regulation and ongoing regulatory review, and the company may be unable to obtain regulatory approval.
• Delays or difficulties in patient enrollment in clinical trials may result in additional costs and delays.
• The company's employees, contractors, and third parties may engage in misconduct or noncompliance with regulatory standards.
• Even if approved, products may fail to achieve broad adoption and commercial success.
• Certain provisions of the company's articles of incorporation, bylaws, and agreements may prevent a change of control that shareholders might consider favorable.
• The price and volume of the company's Common Stock has been and may continue to be volatile.
• The requirements of being a public company may strain resources and divert management's attention.
• Failure to maintain an effective system of internal controls could lead to inaccurate financial reporting or fraud.

Future Outlook

Oragenics plans to apply for an Investigational New Drug (IND) application with the FDA for ONP-002 and expects to initiate patient enrollment for its Phase 2a feasibility study in New Zealand in Q2/Q3 2025, followed by a Phase 2b study in the US. The company projects first revenues from licensing or early access in 2028. It anticipates needing to raise additional capital to complete the development and commercialization of ONP-002 through regulatory approval and is committed to undertaking transactions to achieve compliance with NYSE American listing requirements.

Management Comments

• "The Company is committed to undertaking a transaction or transactions in the future to achieve compliance with the NYSE Americans requirements."
• "We anticipate preparing for Phase 2 clinical trials to further evaluate the ONP-002 drugs safety and efficacy, but our ability to do so is uncertain."
• "Based on the Phase 1 data, we plan to apply for an Investigational New Drug application with the FDA and conduct a Phase 2 trial in the United States."
• "We believe the nasal cavity provides access for our novel neurosteroid formulation to enter the brain in minutes."
• "We believe that our recent work has increased the final dose levels significantly while also providing for improved intranasal drug delivery and adhesion and, thus, longer absorption times."
• "We further believe we have successfully completed an improved proprietary formulation of the ONP-002 drug that should significantly increase the bioavailability of the intranasal drug formulation."
• "Our newly developed proprietary intranasal drug formulation is intended to reduce the duration of initial concussion symptoms and prevent long-lasting symptoms that can be debilitating after a concussion."

Industry Context

Oragenics operates within the highly capital-intensive and regulated biopharmaceutical industry, specifically targeting neurological disorders like mild traumatic brain injury (mTBI) with its lead candidate ONP-002. The company's focus on intranasal drug delivery for neurosteroids represents an innovative approach to potentially achieve rapid and direct brain accessibility. Its strategic partnership with BRAINBox Solutions aligns with a broader industry trend towards integrated diagnostic and therapeutic platforms, aiming to improve patient outcomes through combined early diagnosis and targeted treatment. However, the company faces intense competition from larger, more established players with significantly greater resources, a common challenge for development-stage biotechs.

Corporate Governance

Related Party Transactions

• The company's employment agreement with Janet Huffman, Chief Executive Officer and Chief Financial Officer, is filed as an exhibit.

Stakeholder Impact

• **Shareholders**: Face significant immediate and potential future dilution from the Series H Preferred Stock offering and its anti-dilution provisions. The ongoing NYSE American listing issues and the auditor's going concern doubt pose substantial risks to share price and investment value. Liquidity for the new Preferred Stock and Warrants will be limited due to no established public market.
• **Employees**: The company has equity incentive plans (stock options, stock-based awards) which could be impacted by dilution or changes in stock price. The company's ability to attract and retain qualified personnel may be affected by its financial stability and listing status.
• **Customers/Patients**: The successful development and potential commercialization of ONP-002 for mTBI could offer a new therapeutic option, benefiting patients. However, the uncertainty of regulatory approval and commercial success means this benefit is not assured.
• **Suppliers/Manufacturers**: The company's reliance on third-party suppliers and manufacturers means their operational stability and ability to meet requirements are crucial for the company's R&D progress. Financial instability could impact relationships with these partners.
• **Creditors**: The $3 million Bridge Note is a priority for repayment from the offering proceeds. Failure to raise sufficient funds could lead to default, impacting creditor relationships and the company's ability to secure future debt financing.

Next Steps

• Initiate patient enrollment for the Phase 2a feasibility study of ONP-002 in New Zealand (expected Q2/Q3 2025).
• Complete Phase 2a enrollment (expected Q4 2025).
• Conduct interim safety and biomarker readout for Phase 2a (expected Q4 2025 Q1 2026).
• Initiate Phase 2b (Part B) clinical trial (expected Q2 2026).
• Obtain topline Phase 2b results (expected Q1 2027).
• Hold an FDA End-of-Phase 2 Meeting (expected Q2 2027).
• File for FDA Accelerated Approval (if eligible) (expected Q3 2027).
• Achieve compliance with NYSE American continued listing standards by October 18, 2025.
• Repay the $3 million Bridge Note by its maturity date of July 14, 2025.
• Seek additional capital to complete the development and commercialization of ONP-002 through regulatory approval.
• Potentially increase authorized shares if necessary to satisfy future Preferred Stock conversions.

Key Dates

Recommendation

Keywords

Oragenics, ONP-002, Series H Preferred Stock, Warrants, Traumatic Brain Injury, Concussion, Biopharmaceutical, Clinical Trials, SEC Filing, S-1, Capital Raise, Dilution, NYSE American, Going Concern, Neurosteroid, Drug Development, Biotech